Updated Tuesday, September 26, 2017
JCIM & JIM
Open Access
THIS ARTICLE
-  Abstract
-  Full text
-  Download PDF file
-  Send to a friend
-  Related articles in JCIM & JIM
-  Cited in JCIM & JIM
-  Reader's comments
-  Send a comment
 Language Polishing
Systematic Review
Journal of Chinese Integrative Medicine: Volume 10, 2012   Issue 2
Systematic review and meta-analysis of randomized controlled trials of Chinese herbal medicine in treatment of multiple sclerosis
1. Jian Liu (Department of Encephalopathy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China )
2. Ying Gao (Department of Encephalopathy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China E-mail: gaoying973@126.com)
3. Bao-hong Kan (Department of Encephalopathy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China )
4. Li Zhou (Department of Encephalopathy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China )
BACKGROUND: Chinese herbal medicine (CHM) has been widely used in the treatment of multiple sclerosis (MS). However, there is no systematic review to assess the efficacy and safety of CHM.
OBJECTIVE: To systematically evaluate the efficacy and safety of CHM in the treatment of MS.
SEARCH STRATEGY: Literature was searched from the China National Knowledge Infrastructure Database, the Chinese Biomedical Database (SinoMed), the Chongqing VIP Chinese Science and Technology Periodical Database, Wanfang Data, PubMed and the Cochrane Library. The time limitation ran from the commencement of each database to March 15, 2011.
INCLUSION CRITERIA: Randomized controlled trials (RCTs) testing CHM alone or in combination with Western medicine (WM) against WM or placebo used alone were included.
DATA EXTRACTION AND ANALYSIS: Two authors collected the data respectively. The assessment of methodological quality was based on the Cochrane Handbook and the data were analyzed by using RevMan 5.1.0 software. The efficacy measure was mean difference (MD) with a 95% confidence interval (CI).
RESULTS: After screening of the search results, 16 eligible RCTs with 913 cases were included. The included trials were all of low quality. Thirteen studies adopted Kurtzke Extended Disability Status Scale (EDSS) and two of them showed that EDSS in the treatment group was lower than that in the control group, and the MD and 95% CI were -0.88 (-1.26, -0.50). We performed descriptive analysis on the other eight studies which showed that EDSS of the treatment group was lower than that of the control group. Five studies adopted recurrent frequency and two of them showed that recurrent frequency in the treatment group was lower than that in the control group, and the MD and 95% CI were -0.34 (-0.52, -0.16). We performed descriptive analysis on the other three studies which showed that EDSS in the treatment group was lower than that in the control group. Analyses of secondary outcomes such as clinical symptom score, neurological sign score and immune indexes showed that integrated TCM and WM was more effective than WM treatment alone. The studies displayed that the number or range of magnetic resonance imaging lesion of the treatment group was lower than that of the control group, but there was no statistical significance. The reported adverse events in the CHM group were less than those in the control group.
CONCLUSION: CHM could improve neurological signs, clinical symptoms and immune indexes, and reduce recurrent frequency. The reported adverse events in the CHM group were less than those in the control group. However, further well-designed research is needed to evaluate the beneficial effects of CHM.

Received September 15, 2011; accepted October 17, 2011; published online February 15, 2012.
Full-text LinkOut at PubMed. Journal title in PubMed: Zhong Xi Yi Jie He Xue Bao.

基金项目:国家自然科学基金资助项目(No. 81072770); 北京中医药大学自主选题资助项目(No. 2011JYBZZ-JS015)
Correspondence: Ying Gao, MD, Professor; Tel: 010-84013148; E-mail: gaoying973@126.com

Full text of this article is in Chinese

  
References
1. Wang WZ. Neurology[M]. Beijing: People’s Medical Publishing House, 2006. 1137, 1143. Chinese.
2. Wang YL, Lou JY, Xie P. Basical and clinical research in multiple sclerosis[M]. Zhengzhou: Zhengzhou University Press, 2009. 31, 283, 389. Chinese.
3. Wang YY, Zhang BL. Traditional Chinese medicine encephalopathy[M]. Beijing: People’s Medical Publishing House, 2007. 825, 834. Chinese.
4. Chen KJ. Practical integrated traditional Chinese and Western internal medicine[M]. Beijing: Joint Publishing House of Beijing Medical University and Peking Union Medical College, 1998. 1646. Chinese.
5. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”[J]. Ann Neurol, 2005, 58(6) : 840-846.
    
6. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis: guidelines for research protocols[J]. Ann Neurol, 1983, 13(3) : 227-231.
    
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)[J]. Neurology, 1983, 33(11) : 1444-1452.
  
8. Higgins JPT, Green S, the Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. (2011-03) [2011-05]. http://www.cochrane-handbook.org.
9. Liu JP. The analysis of meta-analysis and forest plot. In: Shi YK. Educational book and proceedings of the 3rd Chinese Conference on Medical Oncology[M]. Beijing: Peking Union Medical College Press, 2010. 220-226. Chinese.
  
10. Liu M. Design and implementation method of systematic review and meta-analysis[M]. Beijing: People’s Medical Publishing House, 2011. 100. Chinese.
11. Zhang JH, Shang HC, Zhang BL. How to assess the quality of systematic review and meta-analysis[J] J Chin Integr Med, 2008, 6(4) : 337-340. Chinese with abstract in English.
  
12. Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition)[J] J Chin Integr Med, 2009, 7(9) : 889-896. Chinese with abstract in English.
  
13. Liu XY, Sun Y, Xie DZ, Liu WJ, Yan XP, Wang LF, Xu BY, Wang AM, Li YR. Clinical and mechanism study of Bushen Shengsui formula in treating multiple sclerosis[M]. Hangzhou: Proceedings of the 4th International Symposium on Integrated Traditional Chinese and Western Medicine in Nervous System Diseases, 2002. 146-148. Chinese.
  
14. Shi LH, Wang QW. Treatment of multiple sclerosis with integrated traditional Chinese and Western medicine[J]. Guangxi Zhong Yi Yao, 2004, 27(2) : 14-17. Chinese.
  
15. Li YL. The clinical research on Jiweiling Capsule in dealing with multiple sclerosis. Shijiazhuang: Hebei Medical University. 2005. Chinese with abstract in English.
  
16. Liu GH, Zhang ZQ. Bushen Tongluo formula in treating 30 patients with multiple sclerosis[J]. Henan Zhong Yi, 2006, 26(11) : 41-42. Chinese.
  
17. Wang YH, Zhao H, Huang JQ, Su ZL. Clinical study on Jiweiling decoction in treating multiple sclerosis[J]. Xian Dai Zhong Xi Yi Jie He Za Zhi, 2006, (12) : 1608-1609. Chinese.
  
18. Zhang GZ, Zhang JS. Clinical study on Gusui Tongluo formula in treating multiple sclerosis[J]. Zhongguo Zhong Yi Ji Zheng, 2006, 15(6) : 595-596. Chinese.
  
19. Zuo SZ, Jia YL. Yishen Gujin Tongluo formula plus Western medicine in treating 30 patients with multiple sclerosis[J]. Zhong Yi Yan Jiu, 2006, 19(8) : 30-32. Chinese.
  
20. Fan YP, Wang P, Zhang XH, Gong HY, Zhou L, Liu XZ, Wang L. Mechanism exploration of Erhuang Formula in treating acute episode of disseminated sclerosis[J]. Zhonghua Zhong Yi Yao Za Zhi, 2007, 22(1) : 25-29. Chinese with abstract in English.
  
21. Fan YP, Wang P, Zhang XH, Gong HY, Zhou L, Liu XZ, Wang L. Treatment of relapsing multiple sclerosis with Erhuang Formula[J]. Beijing Zhong Yi Yao Da Xue Xue Bao, 2006, 29(4) : 273-276, 280. Chinese with abstract in English.
  
22. Gao C, Xie FH, Ou TF, Yang J, Shen YS, Gao M. Anti-inflammatory and immune-modulating effects of Dihuang Heji in the treatment of multiple sclerosis[J]. Zhonghua Shen Jing Yi Xue Za Zhi, 2008, 7(9) : 923-927. Chinese with abstract in English.
  
23. Gao M, Lin MC, Zhang KN, Lin YY, Lü N. Clinical observation of Dihuang Heji capsule in treating 38 patients with acute recurrent multiple sclerosis[J]. Hunan Zhong Yi Za Zhi, 2008, 24(6) : 16-17. Chinese.
  
24. Guo MM, Han QY, Zheng SZ. Observation of effect of Jiannao Tongluo method for preventing multiple sclerosis relapse[J]. Zhongguo Zhong Yi Yao Xian Dai Yuan Cheng Jiao Yu, 2008, 6(1) : 6-7. Chinese.
  
25. Liang H. Effect of Yiguan Jian in micro-lesions of alba in spinal type multiple sclerosis[J]. Zhong Wai Jian Kang Wen Zhai, 2009, 6(26) : 3. Chinese.
  
26. Lin MC. Dihuang Mixture (Capsule) in the treatment of multiple sclerosis in acute relapse phase of clinical research. Guangzhou: Guangzhou University of Chinese Medicine. 2009. Chinese with abstract in English.
  
27. Qian BC. Clinical effect research of Ziyin Guben Decoction to cure multiple sclerosis. Zhengzhou: Henan University of Traditional Chinese Medicine. 2009. Chinese with abstract in English.
  
28. Song LJ. Influence of treatment based on syndrome differentiation mainly with tonifying the kidney on cytokines in plasm of multiple sclerosis at acute stage. Beijing: Capital Medical University. 2009. Chinese with abstract in English.
  
29. Song LJ, Fan YP. Influence of treatment based on syndrome differentiation mainly with tonifying the kidney on cytokines in plasm of multiple sclerosis at acute stage[J]. Zhonghua Zhong Yi Yao Za Zhi, 2010, 25(5) : 745-748. Chinese with abstract in English.
  
30. Zeng HM, Zhang M, Zhang G, Zi XF. Effects of Buyang Huanwu decoction plus glucocorticoid in treating multiple sclerosis[J]. Shi Yong Lin Chuang Yi Xue, 2009, 10(10) : 9-10, 14. Chinese.
  
31. Chen L, Hu WH, Zhi YH, Zhao N. Clinical observation glycosides of Triptergium wilfordii in treating multiple sclerosis[J]. Zhejiang Zhong Yi Yao Da Xue Xue Bao, 2010, 34(2) : 188-189. Chinese.
  
32. Neuroimmunology Unit of Neurology Committee of Chinese Medical Association, Neuro-immunology Committee of Chinese Society for Immunology. Expert consensus on diagnosis and treatment of multiple sclerosis in China[J]. Zhonghua Shen Jing Ke Za Zhi, 2010, 43(7) : 516-521. Chinese.
  
33. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O’Connor PW; International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis[J]. N Engl J Med, 2003, 348(1) : 15-23.
    
34. Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fischer J, Van Dyke C. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis[J]. Ann Neurol, 1995, 37(1) : 30-40.
    
35. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis[J]. Qual Life Res, 1995, 4(3) : 187-206.
    
  
Reader's comments
1. birkenstock online free shipping birkenstock online sale http://birkenstockaustralia.blogspot.com/ (2015-11-15 0:00:00)
2. electra fitflops cheap fitflops online http://fitflopssalesingapore.blogspot.com/ (2015-11-20 0:00:00)
3. fitflops cheap fitflop sandals clearance http://fitflopsau.blogspot.com/ (2015-12-18 0:00:00)
4. louboutin canada christian louboutin outlet canada http://canadachristianlouboutinoutlet.blogspot.com/ (2016-1-13 0:00:00)
5. H05wnA http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com (2016-10-15 0:00:00)
6. H05wnA http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com (2016-10-15 0:00:00)

Send a comment

 Home | Current Issue | Past Issues | SearchRSS
Copyright © 2013-2018 by JIM Editorial Office. All rights reserved. ISSN 2095-4964; CN 31-2083/R. 沪ICP备110264号